Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.63 |
| ▸ | HTT | P42858 | 3/20 | 0.63 |
| ▸ | TSHR | P16473 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3323416 | 0.81 | ALDH1A1 (0.59) | USP2ALDH1A1HTTHSD11B1SMN1; SMN2 | |
| SCHEMBL10016587 | 0.81 | USP2 (0.55) | USP2ALDH1A1HTTKDM4ESMN1; SMN2 | |
| SCHEMBL16026437 | 0.81 | ALDH1A1 (0.83) | ALDH1A1HTTTSHRKDM4ESMN1; SMN2 | |
| SCHEMBL1372144 | 0.75 | ALDH1A1 (0.73) | ALDH1A1HTTTSHRKDM4ESMN1; SMN2 | |
| SCHEMBL3099181 | 0.75 | ALDH1A1 (0.73) | ALDH1A1HTTTSHRKDM4ESMN1; SMN2 | |
| SCHEMBL5992323 | 0.74 | USP2 (0.49) | USP2ALDH1A1HTTTSHRKDM4E | |
| SCHEMBL3093579 | 0.73 | ALDH1A1 (0.71) | ALDH1A1HTTTSHRKDM4ESMN1; SMN2 | |
| SCHEMBL13804475 | 0.73 | ALDH1A1 (0.71) | ALDH1A1HTTTSHRKDM4ESMN1; SMN2 | |
| SCHEMBL1372147 | 0.73 | CYP1A2 (0.75) | ALDH1A1HTTTSHRKDM4ESMN1; SMN2 | |
| SCHEMBL61103 | 0.73 | ALDH1A1 (0.87) | ALDH1A1HTTTSHRKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| EP-1861384-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Sterix Limited (GB) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006100502-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | STERIX LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | HSD3B1, HSD3B2, HSD11B1 | USP2 2756/4885ALDH1A1 437/4885HTT 4393/4885 |
| US-20100120789-A1 | Compound | NR0B2, NR0B1, NR4A1 | USP2 4356/4885ALDH1A1 3143/4885HTT 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.